Dr. Myuri Ruthirakuhan
Dr. Myuri Ruthirakuhan
Post-doctoral Fellow, Sunnybrook Research Institute, University of Toronto
Verified email at
Cited by
Cited by
Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group
P Robert, KL Lanctôt, L Agüera-Ortiz, P Aalten, F Bremond, ...
European Psychiatry 54, 71-76, 2018
Pharmacological interventions for apathy in Alzheimer's disease
MT Ruthirakuhan, N Herrmann, EH Abraham, S Chan, KL Lanctôt
Cochrane Database of Systematic Reviews, 2018
Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review
M Ruthirakuhan, AC Luedke, A Tam, A Goel, A Kurji, A Garcia
Journal of aging research 2012, 2012
Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease
N Herrmann, M Ruthirakuhan, D Gallagher, NPLG Verhoeff, A Kiss, ...
The American journal of geriatric psychiatry 27 (11), 1161-1173, 2019
Is it time to revise the diagnostic criteria for apathy in brain disorders
P Robert, KL Lanctôt, L Agüera-Ortiz, P Aalten, F Bremond, ...
The 2018 international consensus group. Eur Psychiatry 2018; 54: 71 76, 2018
Diagnostic criteria for apathy in neurocognitive disorders
DS Miller, P Robert, L Ereshefsky, L Adler, D Bateman, J Cummings, ...
Alzheimer's & Dementia 17 (12), 1892-1904, 2021
The roles of apathy and depression in predicting Alzheimer disease: a longitudinal analysis in older adults with mild cognitive impairment
M Ruthirakuhan, N Herrmann, D Vieira, D Gallagher, KL Lanctôt
The American Journal of Geriatric Psychiatry 27 (8), 873-882, 2019
Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease
CS Liu, SA Chau, M Ruthirakuhan, KL Lanctôt, N Herrmann
CNS drugs 29 (8), 615-623, 2015
Effect of methylphenidate on apathy in patients with Alzheimer disease: the ADMET 2 randomized clinical trial
J Mintzer, KL Lanctôt, RW Scherer, PB Rosenberg, N Herrmann, ...
JAMA neurology 78 (11), 1324-1332, 2021
A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease
N Herrmann, J O'Regan, M Ruthirakuhan, A Kiss, G Eryavec, E Williams, ...
Journal of the American Medical Directors Association 17 (2), 142-147, 2016
Latrepirdine for Alzheimer's disease
S Chau, N Herrmann, MT Ruthirakuhan, JJ Chen, KL Lanctôt
Cochrane Database of Systematic Reviews, 2015
Three-dimensional quantitative imaging of telomeres in buccal cells identifies mild, moderate, and severe Alzheimer's disease patients
S Mathur, A Glogowska, E McAvoy, C Righolt, J Rutherford, C Willing, ...
Journal of Alzheimer's Disease 39 (1), 35-48, 2014
Natural and synthetic cannabinoids for agitation and aggression in Alzheimer's disease: a meta-analysis
M Ruthirakuhan, KL Lanctôt, D Vieira, N Herrmann
The Journal of clinical psychiatry 80 (2), 2246, 2019
Biomarkers of agitation and aggression in Alzheimer's disease: a systematic review
M Ruthirakuhan, KL Lanctôt, M Di Scipio, M Ahmed, N Herrmann
Alzheimer's & Dementia 14 (10), 1344-1376, 2018
Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study
M Ruthirakuhan, Z Ismail, N Herrmann, D Gallagher, KL Lanctôt
Alzheimer's & Dementia 18 (11), 2199-2208, 2022
Agitation, oxidative stress, and cytokines in Alzheimer disease: biomarker analyses from a clinical trial with nabilone for agitation
M Ruthirakuhan, N Herrmann, AC Andreazza, NPLG Verhoeff, ...
Journal of Geriatric Psychiatry and Neurology 33 (4), 175-184, 2020
Agitation and impulsivity in mid and late life as possible risk markers for incident dementia
DR Bateman, S Gill, S Hu, ED Foster, MT Ruthirakuhan, AF Sellek, ...
Alzheimer's & Dementia: Translational Research & Clinical Interventions 6 (1 …, 2020
Pregnancy and delivery outcomes following benzodiazepine exposure: a systematic review and meta-analysis
S Grigoriadis, L Graves, M Peer, L Mamisashvili, M Ruthirakuhan, P Chan, ...
The Canadian Journal of Psychiatry 65 (12), 821-834, 2020
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease
M Ruthirakuhan, N Herrmann, I Suridjan, EH Abraham, I Farber, ...
Expert opinion on pharmacotherapy 17 (18), 2417-2429, 2016
Pharmacological management of agitation and aggression in Alzheimer’s disease: a review of current and novel treatments
C S Liu, M Ruthirakuhan, S A Chau, N Herrmann, A F Carvalho, ...
Current Alzheimer Research 13 (10), 1134-1144, 2016
The system can't perform the operation now. Try again later.
Articles 1–20